Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | VCP | P55072 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30377316 | 1.00 | NAMPT (0.35) | NAMPTVCPGRM5TRAP1HSP90B1 | |
| SCHEMBL31281765 | 0.88 | TRAP1 (0.35) | NAMPTGRM5TRAP1HSP90B1SIRT2 | |
| SCHEMBL25599287 | 0.88 | TRAP1 (0.35) | NAMPTGRM5TRAP1HSP90B1SIRT2 | |
| SCHEMBL30377606 | 0.87 | NAMPT (0.34) | NAMPTGRM5TRAP1HSP90B1SIRT2 | |
| SCHEMBL25250614 | 0.87 | NAMPT (0.34) | NAMPTGRM5TRAP1HSP90B1SIRT2 | |
| SCHEMBL25254673 | 0.87 | NAMPT (0.33) | NAMPTVCPGRM5TRAP1HSP90B1 | |
| SCHEMBL30377635 | 0.87 | NAMPT (0.33) | NAMPTVCPGRM5TRAP1HSP90B1 | |
| SCHEMBL25599277 | 0.86 | HSP90AA1 (0.39) | NAMPTGRM5TRAP1HSP90B1SIRT2 | |
| SCHEMBL31282001 | 0.84 | TRAP1 (0.36) | TRAP1HSP90B1HSP90AA1HSP90AB1 | |
| SCHEMBL25253982 | 0.83 | EGFR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | claimed |
| EP-4441031-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2024-10-09 | — | — | EP | claimed |
| WO-2023094834-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | claimed |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | disclosed |
| EP-4441031-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023094834-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094834-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | PMS2, MSH2, RECQL | NAMPT 3160/4885VCP 3450/4885GRM5 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.